Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here
Drugs in Development / Clinical Trials—Updated September 17, 2014
Tuesday, September 30, 2014
The deal has been approved by the boards of both companies and is expected to close yet this year.
Partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) has an Alios-developed hepatitis C drug, called ALS-2200 or VS-135, in mid-stage human studies, but Alios’ power for J&J may rest deeper in the company’s portfolio. A number of drugs that Alios is studying, as well as VS-135, tap into the hot area of nucleotides.
The Socialist government said it had designed a "progressive contribution scheme" ensuring all patients can access new and more effective treatments against the liver-destroying virus, while limiting the burden of these drugs on state finances.
The government will selectively tax drugmakers when the total cost to the state from their hepatitis C drugs exceeds a certain amount each year, Health Minister Marisol Touraine said, as she unveiled the country's 2015 social security budget bill on Monday.
Monday, September 29, 2014
Emergency Care – As mentioned, either type of plan would cover you if you went to an Out-of-Network Emergency Room for a life-threatening emergency. In most jurisdictions, courts have ruled that “life-threatening” means as it appears to a lay person, not a physician. A person who goes to an ER with chest pains should have coverage whether it’s a heart attack or simply a bad stomach ache.
Choice of Providers – Almost all HMOs and EPOs contract with large groups of providers who work under a corporate structure. In addition, rather than sign contracts with individual physicians in independent offices, physicians and other providers will form an Independent Practice Association (IPA) and the plan will contract with that umbrella group.
As noted earlier, health plans vary greatly, yet there is no plan that will pay all of the medical bills. However, the amount an insured person must pay out-of-pocket falls into several areas that a plan may or may not have in its schedule.
Does the doctor treat other patients with HCV?
Does he stay current on HCV treatments? Do not hesitate to ask very specific questions, referring to treatments and using terms you have learned in your research on HCV. If they don’t know what you’re talking about, scratch them off your list and move on.
Who are the gastroenterologists, hepatologists, infectious disease specialists, or other HCV knowledgeable specialists that the doctor works with and refers patients to?
The move is an important one because it could ultimately allow Gilead to erase Bristol Myers (NYSE: BMY ) early lead in that market, potentially giving Gilead an opportunity to capture billions of dollars in sales.
Bristol's decision to file for approval first in Japan gives it an early lead over Gilead, which focused on the U.S. and America instead. But if Japan approves the Gilead and ledipasvir combination, that lead may fade quickly.
Sunday, September 28, 2014
New Democrat Health and Long-Term Care critic France Gelinas is calling for a moratorium on the creation of new private health-care clinics and more downloading of hospital services into the community after infectious outbreaks at private clinics in Toronto.
The Nickel Belt MPP said she doesn't want the province to allow the establishment of new private clinics until layers of oversight are in place to guarantee proper care and safety for the patients who visit them.
Gelinas has been making headlines after a Toronto newspaper broke stories about nine people becoming infected with life-threatening bacterial infections, including meningitis, and three private colonoscopy clinics having hepatitis outbreaks since 2011.
“I have known people who died of (hepatitis C) and it’s not a pleasant death,” Davis, 57, told the Journal, saying his diagnosis with the disease in 2013 left him stunned. “I knew what was coming.”
Davis also knew that he couldn’t pay the huge cost of the two-drug treatment he needed.
Saturday, September 27, 2014
Toronto Public Health, which revealed the outbreaks when pressed by the Star, says 11 patients were infected and that tainted sedative injections were the “possible” cause in all cases.
The authorities responsible for investigating the spread of infection and inspecting the clinics — TPH and the College of Physicians and Surgeons of Ontario, respectively — kept the outbreaks secret.